
Vildagliptin (50mg)
Active composition
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Medical applications
Eveglip 50 Tablet contains Vildagliptin 50mg, an oral antidiabetic medication used to manage type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones help regulate blood glucose by enhancing insulin secretion from the pancreas in response to meals and by suppressing glucagon release, thereby reducing hepatic glucose production. Eveglip 50 is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. It is important to take the tablet as directed by a healthcare professional, usually once or twice daily, with or without food. Common side effects may include headache, dizziness, or mild gastrointestinal discomfort, but serious adverse effects are rare. Regular monitoring of blood glucose levels and kidney function is recommended during treatment. Eveglip 50 should be used cautiously in patients with renal impairment and is not indicated for type 1 diabetes or diabetic ketoacidosis. Always consult a healthcare provider before starting or adjusting the dosage.
Pyrrolidine-carbonitrile derivative
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Eveglip 50 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Eveglip 50 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Eveglip 50 Tablet is safe to use in patients with kidney disease. No dose adjustment of Eveglip 50 Tablet is recommended. However, in patients with moderate to severe kidney disease, dose adjustment may be required. Consult with your doctor.
Exercise Caution
Eveglip 50 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Eveglip 50 Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Eveglip 50 Tablet

Vildagliptin (50mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Medical applications
Eveglip 50 Tablet contains Vildagliptin 50mg, an oral antidiabetic medication used to manage type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones help regulate blood glucose by enhancing insulin secretion from the pancreas in response to meals and by suppressing glucagon release, thereby reducing hepatic glucose production. Eveglip 50 is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. It is important to take the tablet as directed by a healthcare professional, usually once or twice daily, with or without food. Common side effects may include headache, dizziness, or mild gastrointestinal discomfort, but serious adverse effects are rare. Regular monitoring of blood glucose levels and kidney function is recommended during treatment. Eveglip 50 should be used cautiously in patients with renal impairment and is not indicated for type 1 diabetes or diabetic ketoacidosis. Always consult a healthcare provider before starting or adjusting the dosage.
Pyrrolidine-carbonitrile derivative
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Eveglip 50 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Eveglip 50 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Eveglip 50 Tablet is safe to use in patients with kidney disease. No dose adjustment of Eveglip 50 Tablet is recommended. However, in patients with moderate to severe kidney disease, dose adjustment may be required. Consult with your doctor.
Exercise Caution
Eveglip 50 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Eveglip 50 Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Eveglip 50 Tablet













